Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to
inflammation of the skin. Therapies spread over the skin may not be enough to control the AD
in trial participants who require systemic anti-inflammatory treatment. This study compares
upadacitinib to dupilumab in adolescent and adult participants with moderate to severe AD who
have inadequate response to systemic therapies. Adverse events and change in the disease
activity will be assessed.
Upadacitinib and dupilumab are approved drugs for the treatment of moderate to severe atopic
dermatitis (AD). The study is comprised of a 35-day Screening Period, a 16-week treatment
period 1 and a 16-week treatment period 2. During period 1, participants are randomly
assigned in 1 of 2 groups, called treatment arms to receive upadacitinib Dose A or dupilumab.
In Period 2, participants will receive upadacitinib Dose A or Dose B. Approximately 880
adolescent and adult participants ages 12 to 64 with moderate to severe AD who are candidates
for systemic therapy will be enrolled at up to 330 sites worldwide.
Participants will receive upadacitinib oral tablets once daily or dupilumab as per its label
for 32 weeks and followed for 30 days.
There may be higher treatment burden for participants in this trial compared to their
standard of care . Participants will attend regular visits during the study at a hospital or
clinic. The effect of the treatment will be checked by medical assessments, blood tests,
checking for side effects and completing questionnaires.

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Rapid City

Health Concepts /ID# 250988

Upadacitinib

Dupilumab

A Phase 3b/4 Randomized, Open-label, Efficacy Assessor Blinded Study, Comparing the Safety and Assessor Blinded Efficacy of Upadacitinib to Dupilumab in Subjects With Moderate to Severe Atopic Dermatitis (Level-Up)

The study consists of Safety Run-in and Phase 2 Cohorts.
The primary objectives of the safety run-in cohorts of this study are to evaluate the safety,
tolerability, and recommended Phase 2 dose (RP2D) of magrolimab in combination with
pembrolizumab + 5-fluorouracil (5-FU) + platinum chemotherapy, and docetaxel in combination
with magrolimab in participants with head and neck squamous cell carcinoma (HNSCC).
Phase 2 Cohorts 1: To evaluate the progression-free survival (PFS) with magrolimab in
combination with pembrolizumab + 5-FU + platinum versus pembrolizumab + 5-FU + platinum as
assessed by independent central review.
Phase 2 Cohorts 2 and 3: To evaluate the efficacy of magrolimab in combination with
pembrolizumab and magrolimab in combination with docetaxel as determined by the
investigator-assessed objective response rate (ORR).

Study of Magrolimab Combination Therapy in Participants With Head and Neck Squamous Cell Carcinoma

Sioux Falls

Avera Cancer Institute

Magrolimab

Pembrolizumab

Docetaxel

5-FU

Cisplatin

Carboplatin

Zimberelimab

A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma

The purpose of this study is to characterize the distribution of lipoprotein(a) (Lp(a))
levels among participants with a history of ASCVD as defined by their medical history and is
2-fold:
-  Evaluate the distribution of Lp(a) value in the overall participants with documented
history of ASCVD
-  Evaluate the distribution of Lp(a) value in participants with documented history of
ASCVD by demographics and regions

A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)

Monument Health Clinical Research

Lp(a) Screening

A Multicenter, Cross-sectional Study to Characterize the Distribution of Lipoprotein(a) Levels Among Patients With Documented History of Atherosclerotic Cardiovascular Disease

This phase III trial studies how well lenalidomide in combination with ixazomib works
compared to lenalidomide alone in treating patients with evidence of residual multiple
myeloma after stem cell transplantation. Lenalidomide may help shrink or slow the growth of
multiple myeloma. Ixazomib may stop the growth of cancer cells by blocking some of the
enzymes needed for cell growth. Giving lenalidomide and ixazomib together may work better
than giving lenalidomide alone in treating patients with evidence of residual multiple
myeloma after a stem cell transplantation.

Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

Sanford USD Medical Center - Sioux Falls

Ixazomib Citrate

Lenalidomide

Placebo Administration

Quality-of-Life Assessment

Questionnaire Administration

Optimizing Prolonged Treatment in Myeloma Using MRD Assessment (OPTIMUM)

This is a Phase III, randomised, open-label, 2 arm, multicentre, international study
assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally
recurrent inoperable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor
therapy.

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Research Site

Dato-DXd

Paclitaxel

Nab-paclitaxel

Capecitabine

Eribulin mesylate

A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02)

The main purpose of this study is to assess the efficacy and safety of Tirzepatide
(LY3298176) in participants with heart failure with preserved ejection fraction and obesity.

A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)

Monument Health Rapid City Hospital

Tirzepatide

Placebo

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)

This post-marketing study is designed to compare the safety of baricitinib versus tumor
necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when
given to participants with rheumatoid arthritis (RA).

A Study of Baricitinib in Participants With Rheumatoid Arthritis

Monument Health Clinical Research, a department of Monument Health Rapid City Hospital, Inc.

Baricitinib

TNF Inhibitor

A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy
(SG) in combination with pembrolizumab given after surgery, is effective and safe compared to
the treatment of physician's choice (TPC) which includes either pembrolizumab or
pembrolizumab plus capecitabine in participants with triple negative breast cancer that still
remains after surgery and pre-surgical treatment.

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Sacituzumab govitecan-hziy (SG)

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

The main purpose of this study is to determine the efficacy and safety of LY3819469 in adults
with elevated lipoprotein(a). The study will lasts about 20 months.

A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]

Care Access - Rapid City

LY3819469

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3819469 in Adults With Elevated Lipoprotein(a)

The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as
monotherapy and in combination in participants with select B-cell lymphomas including mantle
cell lymphoma (MCL), Richter's transformation lymphoma (RTL), follicular lymphoma (FL), and
chronic lymphocytic leukemia (CLL). This study will also evaluate zilovertamab vedotin as
monotherapy and in combination with respect to objective response rate.
-  Cohort A: Participants with relapsed or refractory MCL relapsed or refractory disease
after at least 2 prior systemic therapies including a Bruton's tyrosine kinase
inhibition/inhibitor (BTKi), and post therapy chimeric antigen receptor T (CAR-T) cell
therapy or ineligible for CAR-T cell therapy
-  Cohort B: Participants with relapsed or refractory RT disease after at least 1 prior
systemic therapy
-  Cohort C: Participants with relapsed or refractory MCL relapsed or refractory disease
after at least 1 prior systemic therapy and no prior exposure to a non-covalent BTKi
-  Cohort D: Participants with relapsed or refractory FL and CLL relapsed or refractory
disease after at least 2 prior systemic therapies and have no other available therapy
-  Cohort E: Participants with relapsed or refractory FL after at least 2 prior systemic
therapies and have no other available therapy
-  Cohort F: Participants with relapsed or refractory CLL after at least 2 prior systemic
therapies and have no other available therapy
The primary study hypothesis is that zilovertamab vedotin monotherapy has an increased
Objective Response Rate (ORR) per Lugano Response Criteria as assessed by blinded independent
central review (BICR).

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

Avera Cancer Institute- Research ( Site 0011)

Zilovertamab vedotin

Nemtabrutinib

A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies

South Dakota